Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 3

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 3
---
 at the Special Meeting. We hope that you will join us virtually on [●], 2025. Your investment and continuing interest in Aadi are very much appreciated.

| Sincerely yours,                    |
| David Lennon, Ph.D.                 |
| President & Chief Executive Officer |
| Caley Castelein, M.D.               |
| Chairman of the Board               |

17383 Sunset Boulevard, Suite A250 Pacific Palisades, California 90272 NOTICE OF SPECIAL MEETING OF STOCKHOLDERS To Be Held Online on [● ], [● ], 2025 at www.virtualshareholdermeeting.com/AADI2025SM Notice is hereby given that a special meeting of stockholders (together with any adjournment or postponement thereof, the “Special Meeting”) of Aadi Bioscience, Inc. (“Aadi,” the “Company,” “we” or “us”), will be held online on [●], 2025 at [●] Pacific Time. The Special Meeting will be a virtual meeting, which will be conducted via live webcast. You will be able to attend the meeting virtually via the Internet, vote your shares electronically and submit your questions during the Special Meeting via the Internet at www.virtualshareholdermeeting.com/AADI2025SM. You will need your control number, which is located on the proxy card that you received in the mail or in the instructions accompanying your proxy materials, to attend the Special Meeting. Only stockholders who owned shares of our common stock at the close of business on [●], 2025 can vote at the Special Meeting. At the Special Meeting, stockholders will be asked to consider and vote on the following proposals:

| 1. | Divestiture Proposal. To approve the sale by Aadi to KAKEN INVESTMENTS INC. (“Kaken”) of 100%                                                                                                                                                            
 of the outstanding shares of capital stock of Aadi Subsidiary, Inc. (“Aadi Sub”) and thereby all or substantially all of Aadi’s assets related to its FYARRO® (sirolimus                                                                                 
 protein-bound particles for injectable suspension) (albumin-bound) program the “FYARRO Business”), pursuant to the terms of that certain stock purchase agreement, dated as of December 19, 2024, among Aadi, Kaken, KAKEN PHARMACEUTICAL                
 CO., LTD, Kaken’s parent company and guarantor (“Kaken Parent”) and Aadi Sub (as may be amended from time to